menu
    • menu
    [{"orgOrder":0,"company":"CBL- Chemical and Biopharmaceutical Laboratories","sponsor":"Relaxera Pharmazeutische","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CBL- Chemical and Biopharmaceutical Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CBL- Chemical and Biopharmaceutical Laboratories \/ CBL- Chemical and Biopharmaceutical Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"CBL- Chemical and Biopharmaceutical Laboratories \/ CBL- Chemical and Biopharmaceutical Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals by CBL- Chemical and Biopharmaceutical Laboratories

    Menu

    CBL- Chemical and Biopharmaceutical Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CBL- Chemical and Biopharmaceutical Laboratories

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CBL- Chemical and Biopharmaceutical Laboratories

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : Relaxera Pharmazeutische

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human Relaxin-2

                            Details : This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 16, 2020

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : Relaxera Pharmazeutische

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth